161 related articles for article (PubMed ID: 35017636)
1. The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.
Machino H; Kaneko S; Komatsu M; Ikawa N; Asada K; Nakato R; Shozu K; Dozen A; Sone K; Yoshida H; Kato T; Oda K; Osuga Y; Fujii T; von Keudell G; Saloura V; Hamamoto R
Commun Biol; 2022 Jan; 5(1):39. PubMed ID: 35017636
[TBL] [Abstract][Full Text] [Related]
2. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
3. Loss of LKB1-NUAK1 signalling enhances NF-κB activity in a spheroid model of high-grade serous ovarian cancer.
Buensuceso A; Fritz JL; Collins O; Valdés YR; Borrelli MJ; DiMattia GE; Shepherd TG
Sci Rep; 2022 Feb; 12(1):3011. PubMed ID: 35194062
[TBL] [Abstract][Full Text] [Related]
4. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
[TBL] [Abstract][Full Text] [Related]
5. AMPKα-like proteins as LKB1 downstream targets in cell physiology and cancer.
Molina E; Hong L; Chefetz I
J Mol Med (Berl); 2021 May; 99(5):651-662. PubMed ID: 33661342
[TBL] [Abstract][Full Text] [Related]
6. Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer.
Tanwar PS; Mohapatra G; Chiang S; Engler DA; Zhang L; Kaneko-Tarui T; Ohguchi Y; Birrer MJ; Teixeira JM
Carcinogenesis; 2014 Mar; 35(3):546-53. PubMed ID: 24170201
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
[TBL] [Abstract][Full Text] [Related]
8. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.
Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS
Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169
[TBL] [Abstract][Full Text] [Related]
9. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
Wang Y; Qiu C; Lu N; Liu Z; Jin C; Sun C; Bu H; Yu H; Dongol S; Kong B
Int J Oncol; 2018 Jun; 52(6):2130-2142. PubMed ID: 29620165
[TBL] [Abstract][Full Text] [Related]
10. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.
Wu H; Li R; Zhang Z; Jiang H; Ma H; Yuan C; Sun C; Li Y; Kong B
J Ovarian Res; 2019 Dec; 12(1):125. PubMed ID: 31884974
[TBL] [Abstract][Full Text] [Related]
11. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.
Park SH; Song JY; Kim YK; Heo JH; Kang H; Kim G; An HJ; Kim TH
Int J Oncol; 2014 Mar; 44(3):637-46. PubMed ID: 24378809
[TBL] [Abstract][Full Text] [Related]
12. ACSM3 suppresses the pathogenesis of high-grade serous ovarian carcinoma via promoting AMPK activity.
Yang X; Wu G; Zhang Q; Chen X; Li J; Han Q; Yang L; Wang C; Huang M; Li Y; Chen J; LiLi ; Wang H; Liu K
Cell Oncol (Dordr); 2022 Feb; 45(1):151-161. PubMed ID: 35124784
[TBL] [Abstract][Full Text] [Related]
13. SOCS7/HuR/FOXM1 signaling axis inhibited high-grade serous ovarian carcinoma progression.
Du Y; Xu X; Lv S; Liu H; Sun H; Wu J
J Exp Clin Cancer Res; 2022 May; 41(1):185. PubMed ID: 35624501
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor LKB1 inhibits the progression of gallbladder carcinoma and predicts the prognosis of patients with this malignancy.
Hu MT; Wang JH; Yu Y; Liu C; Li B; Cheng QB; Jiang XQ
Int J Oncol; 2018 Sep; 53(3):1215-1226. PubMed ID: 30015925
[TBL] [Abstract][Full Text] [Related]
16. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
17. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
Liu Z; Gersbach E; Zhang X; Xu X; Dong R; Lee P; Liu J; Kong B; Shao C; Wei JJ
Mol Cancer Res; 2013 Nov; 11(11):1314-25. PubMed ID: 24045973
[TBL] [Abstract][Full Text] [Related]
18. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
[TBL] [Abstract][Full Text] [Related]
19. Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis.
George SH; Milea A; Sowamber R; Chehade R; Tone A; Shaw PA
Oncogene; 2016 Jan; 35(1):59-68. PubMed ID: 25798842
[TBL] [Abstract][Full Text] [Related]
20. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma.
Dong R; Liu X; Zhang Q; Jiang Z; Li Y; Wei Y; Li Y; Yang Q; Liu J; Wei JJ; Shao C; Liu Z; Kong B
Oncotarget; 2014 Nov; 5(21):10816-29. PubMed ID: 25333261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
